A multidisciplinary program for meningioma treatment, research, and support services.

BACKGROUND

Standard treatments for meningioma include surgery and radiotherapy, but the timing and technical details of these treatments are debated, particularly as advances in meningioma biology expand options for treatment. Patients with meningioma may experience adverse quality-of-life and neurocognitive sequelae following diagnosis and treatment, and survivorship resources for these patients are limited.

METHODS

We initiated a Multidisciplinary Meningioma Program (MMP) to advance the care of patients at our institution in September 2024. The MMP consists of synergistic clinical, scientific, and survivorship resources, including a weekly tumor board and multidisciplinary clinic, clinical trials and prospective registries for translational research, a meningioma-specific support group, and basic and translational research. In this article, we describe the implementation and initial patient-facing aspects of the MMP.

RESULTS

In the first 15 months of the MMP, 602 cases were discussed at the MMP tumor board, and 142 patients were seen in consultation in the MMP multidisciplinary clinic. Twelve percent of patients discussed in the MMP tumor board were offered clinical trial enrollment, and 84% were offered prospective registry enrollment. Participants in the MMP support group cited informational and emotional benefits. Following implementation of the MMP, the clinical volume of consultations for meningioma increased by 87.0%-533.3%, and the volume of treatments increased by 42.1%-115.2% across clinical departments.

CONCLUSIONS

Through creation of a multidisciplinary program for meningioma treatment, research, and support services, we enabled consensus clinical recommendations, streamlined enrollment on clinical trials and prospective registries, improved access to support services, and increased patient volume.